NASDAQ$ANIK

Anika Therapeutics Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Reported strong Q4 and full year results, including a record year in OA Pain Management, and announced cost reduction initiatives.

Anika Therapeutics reported strong fourth quarter and full year results, with a record year in OA Pain Management. The company is implementing cost reduction initiatives expected to provide annualized savings of approximately $10 million. Anika anticipates adjusted EBITDA of $25 to $30 million in 2024.

  • Achieved record annual revenues in OA Pain Management, up 11% in 2023.
  • Launched multiple meaningful new products and made considerable progress addressing the new MDR regulatory requirements in Europe.
  • Announced cost reduction initiatives providing annualized savings of approximately $10 million.
  • Positioned to generate adjusted EBITDA of $25 to $30 million in 2024, up over 75% at the midpoint.

Headline financials

Total Revenue

$43M

Previous: $39.6M+8.5%
EPS (adj)

$0.05

Previous: -$0.21+123.8%
Capital Expenditures

$1.84M

Previous: $2.53M-27.2%
Net Income

-$63M

Previous: -$4.91M-1183.6%
Operating Income

-$1.59M

Previous: -$6.67M+76.1%
Gross Profit

$26.3M

Previous: $24.1M+9.1%
R&D Expense

$7.59M

No prior period
Stock-Based Comp

$3.82M

Previous: $3.81M+0.1%

Revenue & EPS history

Anika · Revenue · Quarterly

$43M

Q4 2023+8.5%vs Q4 2022
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Forward guidance

Anika expects revenue for fiscal year 2024 of $168 to $173 million, representing growth of 1% to 4% compared to 2023. The Company expects adjusted EBITDA for 2024 to be $25 to $30 million, up over 75% at the midpoint, representing an adjusted EBITDA margin of at least 15%, up over 6 points compared to 2023.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+0.1%

Avg return

Earnings day

-3.0%

Avg return

5 days after

-2.8%

Avg return

30 days after

51%

33 / 65 earnings

Positive

+32.1%

Q3 2019

Best reaction

-33.0%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-18.8%-4.7%-4.8%
Q4 2025+16.8%+31.6%+30.5%
Q3 2025+0.8%-0.5%+2.1%
Q1 2025-20.7%-23.2%-23.0%
Q4 2024-11.1%-7.3%-20.3%
Q3 2024-33.0%-34.0%-28.2%
Q2 2024-1.0%-3.6%-5.4%
Q1 2024-10.9%-9.9%-9.1%
Q4 2023-4.8%-2.0%-3.1%
Q3 2023+7.4%+6.7%+15.2%
Q2 2023-4.9%-12.7%-18.0%
Q1 2023-2.8%-3.2%+3.2%
Q4 2022-18.0%-17.4%-10.4%
Q3 2022+0.3%+5.3%+6.3%
Q2 2022-4.9%-2.7%-6.0%
Q1 2022-4.9%-3.8%+1.1%
Q4 2021-15.9%-18.0%-20.1%
Q3 2021+3.1%-8.2%-12.8%
Q2 2021+1.0%+0.8%+1.3%
Q1 2021+1.3%+2.8%+10.9%
Q4 2020-10.5%-12.1%+3.9%
Q3 2020-3.3%+0.2%+7.6%
Q2 2020+0.3%-8.7%+2.9%
Q1 2020-9.9%-12.2%+9.1%
Q4 2019+0.4%+0.1%-39.5%
Q3 2019+32.1%+21.5%+3.7%
Q2 2019+29.1%+31.0%+37.2%
Q1 2019+19.6%+21.5%+15.9%
Q4 2018-15.3%-18.8%-26.5%
Q3 2018-11.0%-13.6%-13.9%
Q2 2018+18.6%+15.0%+20.8%
Q1 2018-22.9%-15.7%-8.6%
Q4 2017-4.0%-11.3%-17.4%
Q3 2017-8.0%-9.2%-8.0%
Q2 2017+7.1%+6.0%+9.3%
Q1 2017-5.5%-1.8%+0.4%
Q4 2016-5.0%-5.1%-16.4%
Q3 2016+2.0%+2.7%+8.0%
Q2 2016-5.0%-2.3%-6.7%
Q1 2016+0.5%
Q4 2015+11.2%
Q3 2015+12.5%
Q2 2015+3.2%
Q1 2015-7.5%
Q4 2014-10.7%
Q3 2014+1.0%
Q2 2014+4.1%
Q1 2014+7.7%
Q4 2013+26.9%
Q3 2013+6.5%
Q2 2013+21.9%
Q1 2013-1.8%
Q4 2012+16.6%
Q3 2012-7.7%
Q2 2012+24.4%
Q1 2011+0.6%
Q1 2012+2.8%
Q4 2009+1.5%
Q4 2011+1.5%
Q3 2011+7.0%
Q3 2010+7.0%
Q2 2010-3.4%
Q4 2010-3.4%
Q2 2011-3.4%
Q1 2010-1.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro